Physician profile
B Michael Samek
NPI 1326013756
$2,007.47
in general payments reported to CMS, 2019-2025
15 companies · $489 in 2025
The $489 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2021: $112 · 2022: $263 · 2023: $73.00 · 2024: $791 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154 · Travel and Lodging: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.77 |
| Travel and Lodging | $199.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $619.93 | 2024-2025 | Misight Contact Lens |
| Alcon Vision LLC | $380.77 | 2019-2025 | Tryptyr, Eysuvis, Dailies Total1 |
| Sun Pharmaceutical Industries INC. | $246.65 | 2021-2025 | |
| Horizon Therapeutics Plc | $124.96 | 2022 | |
| Bausch & Lomb Americas INC. | $111.74 | 2023-2025 | Miebo, Infuse, Xiidra |
| Optos, INC. | $96.88 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $92.96 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.11 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $55.13 | 2022-2025 | |
| Allergan, INC. | $53.96 | 2021-2022 | |
| Oyster Point Pharma, INC. | $44.48 | 2023-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $40.24 | 2021-2022 | |
| Thea Pharma INC. | $32.00 | 2023-2025 | Iyuzeh |
| Biotissue Holdings INC. | $21.60 | 2022 | |
| Kala Pharmaceuticals, INC. | $21.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw B Samek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.